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ABSTRACT 
We report here the synthesis and mechanism of inhibition of pyrazolecarboxamide derivatives as a new 
class of HCV inhibitors. Compounds 5, 7, 11, and 12 inhibited the subgenomic HCV replicon 1b geno-
type at EC50 values between 5 to 8 μM and displayed an even higher potency against the infectious Jc1 
HCV 2a genotype. Compound 12 exhibited an EC50 of 6.7 μM and selectivity index of 23 against HCV 
1b, and reduced the RNA copies of the infectious Jc1 chimeric 2a clone by 82% at 7 μM. Evaluation of 
the mode of anti-HCV activity of 12 revealed that it suppressed HCV-induced COX-2 mRNA and pro-
tein expression, displaying an IC50 of 3.2 μM in COX-2 promoter-linked luciferase reporter assay. 
Conversely, the anti-HCV activity of 12 was abrogated upon over-expression of COX-2. These find-
ings suggest that these pyrazolecarboxamides function as anti-HCV agents via targeting COX-2 at both
the transcription and translation levels. 
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INTRODUCTION 
Hepatitis C virus (HCV), a single stranded positive sense RNA virus, is a causative agent of 
hepatitis C, a disease that affects 3% of the world population, an estimated 200 million people world-
wide. The global incidence of HCV infection is underestimated as the acute infection is generally 
asymptomatic. Eighty percent of HCV infections lead to chronic liver disease that have the potential to 
evolve into fibrosis, cirrhosis and hepatocellular carcinoma.1-3 Both prophylaxis of HCV infection and 
vaccine development have been quite unsuccessful so far.4 
Treatment of HCV infections with peg-IFN, wherein INF-α is covalently bound to polyethylene 
glycol, in combination with the synthetic guanosine analogue Ribavirin, has demonstratedsevere ad-
verse effects in a large number of patients. The sustained viral response rate to this treatment was also 
very low in patients infected with HCV genotype 1, the predominant genotype in the western coun-
tries.5,6 In 2011, the FDA approved the first direct-acting antiviral agents (DAAs) Boceprevir and
Telaprevir for the treatment of chronic hepatitis C genotype 1 infection in combination with pegIFN-2α 
or -2β, and Ribavirin.7,8 However, despite improved response rates, combination treatments including
either Boceprevir or Telaprevir show the rapid selection of drug-resistant viral mutants,9 limited antivi-
ral efficacy in patients with HCV genotypes 2-6 infections and long-term toxic effects.8,10 Therefore,
new HCV agents are under investigation towards either non-structural proteins or host factors. 
We have developed a reference model for the anti-HCV agents (Chart 1). Consistent with this 
model, a built-in 5-membered heterocyclic core (A) sustains two nearby cyclic substituents (B, C), and 
a short linker (D), also represented by an aromatic ring, bearing an optional non-hydrophobic group 
(E). In continuation of our studies on pyrazole agents,11 we observed that N,1-diphenyl-5-(1H-pyrrol-1-
yl)-1H-pyrazole-3-carboxamide (4), a pyrazolecarboxamide previously synthesized by us, as well as 
some known HCV inhibitors (i.e. 1,12 213 and 314), well matched the requirements of this reference 
model. 
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Chart 1. Reference Model and Structures of Compounds 1-21.a 
a4-21: R1 = H, 4-Cl; R2 = H, 4-Cl, 4,3-Cl2; R3 = H, CN, Me. 
In a preliminary screening, compound 4 showed significant inhibition of the HCV replicon 1b 
(Con 1 strain) in Huh 5-2 cells with an EC50 of 31.7 µM (Table 1), and it was predicted to have drug-
like properties by QikProp software (Table 2). These results prompted the synthesis of the new 1-
phenyl-5-(1H-pyrrol-1-yl)pyrazolecarboxamides 5-21, in order to analyse the potential for productive
modifications of 4, in a quest to discover new potent anti-HCV agents. 
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Scheme 1. Synthesis of pyrazole-3-carboxamides 4-19 and 
pyrazole-4-carboxamides 20,21.a,b 
aCarboxamides 4-21, see Table 1 for R1, R2 and R3. Carboxylic ac-
ids: 22, R1 = R3 = H; 23, R1 = H, R3 = CN; 24, R1 = 4-Cl, R3 = H; 
25, R1 = 4-Cl, R3 = CN; 26, R1 = H, R3 = Me; 27, R1 = 4-Cl, R3 = 
Me; 28, R1 = 4-Cl, R3 = H. 
bReagents and conditions. (a): (5-19) (i) 1,1'-carbonyldiimidazole, 
anhydrous THF, 25 °C, 3 h; (ii) aniline (6,10,12,14), 4-
chloroaniline (5,7,9,11,13,15) or 3,4-dichloroaniline (16-19), 25 
°C, 24 h, 10-83%; (b): (4, 20, 21) aniline (4, 20), 4-chloroaniline 
(21) BOP reagent, triethylamine, anhydrous DMF, 25 °C, 12 h, 13-
70%. 
CHEMISTRY 
Carboxamides 5-19 were obtained by reaction of carboxylic acids 22-27 with 1,1'-
carbonyldiimidazole in anhydrous THF at 25 °C, and subsequent treatment of the imidazolide interme-
diates with appropriate anilines (Scheme 1). Carboxamides 4, 20 and 21 were obtained by reaction of 
acids 22 or 28 and with the appropriate anilines in the presence of BOP reagent and triethylamine in
anhydrous DMF at 25 °C. The corresponding carboxylic acids, 22-27,11c and 2815 were synthesized by
following our earlier reported procedures. 
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Table 1. Anti-HCV activities of compound 4-21. 
Replicon 1b, Con 1 strain, 
Huh 5-2 Cells (µM)a 
Compd R1 R2 R3 CC50b EC50c EC90d SIe 
4 H H H >228 31.7 ± 7.3 ndf >3.1 
5 H 4-Cl H 120.2 5.9 ± 1.3 nd 20.4 
6 H H CN >247.6 39.6 ± 7.6 >241 >6.25 
7 H 4-Cl CN 137.7 7.8 ± 0.3 nd 17.6 
8 4-Cl H H >241.1 26.9 ± 13.1 >206.7 >8.9 
9 4-Cl 4-Cl H >220.3 35.4 ± 6.7 170.9 >6.2 
10 4-Cl H CN 202.5 26.2 ± 6.5 nd 7.7 
11 4-Cl 4-Cl CN 151.7 5.5 ± 1.1 129.5 27.3 
12 H H Me >153.8 6.7 ± 1.7 nd 23 
13 H 4-Cl Me 193.7 16.5 ± 6.0 61.8 11.7 
14 4-Cl H Me >232.2 16.7 ± 2.2 57.1 13.8 
15 4-Cl 4-Cl Me >160.1 13.6 ± 2.4 nd >11.8 
16 H 3,4-Cl2 H >220.3 39.8 ± 3.2 nd >5.5 
17 4-Cl 3,4-Cl2 H >202.7 >159.0 nd >1.3 
18 H 3,4-Cl2 CN >207.2 108.1 ± 13.4 nd >1.9 
19 4-Cl 3,4-Cl2 CN >257.3 50.5 ± 1.5 nd 5.1 
20 4-Cl H H >241.2 >241.2 nd nd 
21 4-Cl 4-Cl H 62.6 13.7 ± 0.9 nd 4.7 
aThe data represent an average of at least two independent measurements in duplicate ± SD. bCC50: concentration of 
compound that reduces the overall cellular metabolic activity by 50% (MTS-based assay). cEC50, dEC90: effective 
concentration of compound that inhibits the virus replication by 50% or 90%, respectively (luciferase-based assay). 
eSI: selectivity index, CC50/EC50 ratio. fnd: not determined. 
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RESULTS AND DISCUSSION 
Inhibition of HCV Replicon 1b in Huh 5-2 Cells. Compared to 4, compound 5 (EC50 = 5.9
μM) bearing a chlorine atom at position 4 of the 3-(phenylaminocarbonyl)pyrazole moiety, yielded a 
5.4-fold improvement of the antiviral activity. Similarly, the 3-[(4-chlorophenyl)aminocarbonyl]-4-
cyanopyrazole derivative 7 (EC50 = 7.8 μM) was 5.1-fold more potent than the parent compound 6 
(EC50 = 39.6 µM). In contrast, when a 3,4-dichlorophenyl moiety was introduced (compounds 16-19), a 
reduction in the antiviral activity was observed. Introduction of a chlorine atom at the pendant 1-phenyl 
group of 7, to give the corresponding 1-(4-chlorophenyl)pyrazole derivative 11 resulted in a strong re-
plicon inhibition with EC50 = 5.5 μM. 
Replacement of the cyano substituent at position 4 of the pyrazole with the methyl group (12, 
EC50 = 6.7 μM), yielded 5.9- and 4.7-fold improvements in the antiviral activity relative to 6 and 4, re-
spectively. Furthermore, when the phenylaminocarbonyl moiety was shifted from position 3 to 4 of the 
pyrazole nucleus, a dramatic reduction (>9-fold) of the HCV replicon activity was observed (compare 
20 with 8). However, the inhibitory activity was restored when the (4-chlorophenyl)aminocarbonyl 
moiety was placed at position 4 of the pyrazole (21, EC50 = 13.7 μM). 
In summary, the most pronounced antiviral activity was obtained when a chlorine atom was in-
troduced at position 4 of the phenylaminocarbonyl moiety (compounds 5, 7, 11). In comparing position 
3 with 4 of the pyrazole, the phenylaminocarbonyl moiety at position 3 resulted in higher selectivity 
(compare 8 and 9 with 20 and 21). Compounds 5, 7, 11 and 12 were the most potent inhibitors of the 
HCV replicon within this series with inhibitory concentrations (EC50 values) in the lowest micromolar 
range of concentration. The most active derivative 11 also elicited the highest selectivity index (11: 
EC50 = 5.5 μM; SI = 27.3). 
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Figure 1.  Antiviral activity of compounds 4, 5 and 12 on HCV Jc1 infected cells. Huh 7.5 cells were infected at 1 m.o.i.  in 
12 wells plates. Six h post-infection, cells were treated for 72 h with either DMSO (control) or compounds 4 (10 µM), 5 (6 
µM) or 12 (7 µM). Cells were harvested and processed for total RNA isolation and one step qRT-PCR. *p˂ 0.05; **p˂0.01. 
Inhibition of HCV-Jc1 virus infected Huh 7.5 cells. We investigated the antiviral activity of 
three representative compounds, 4, 5 and 12, in HCV infected Huh 7.5 cells, using the most advanced 
HCV infectious system based on RNA transfection and subsequent infection of Huh7.5 cell line with 
HCV genotype 2a infectious chimeric clone Jc1.16 In the Jc1 system, the compounds were initially 
screened at the EC50 values obtained in Huh 5-2 replicon 1b cells. Compounds 4, 5 and 12 at concentra-
tions of 10 µM, 6 µM and 7 µM, respectively, reduced the intracellular RNA copies of HCV genome 
by 70%, 68% and 82% (Figure 1), thus  exhibiting higher potency in the Jc1 system than in the replicon 
1b cells. These results suggest that treatment with compound 4 as well as with its analogues 5 and 12 
effectively inhibited HCV infection in vitro. 
Inhibition of HCV NS5B RdRp. To investigate whether the anti-HCV activity of compounds 
4-21 is mediated through targeting HCV NS5B, we evaluated NS5B RdRp activity by the standard 
Page 9 of 30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9 
primer-dependent elongation reaction employing poly rA/rU12 template-primer and recombinant HCV 
NS5BCΔ21.17 However, either no inhibition or considerably poor inhibition (data not shown) of RdRp
activity of NS5B was observed, suggesting that the observed anti-HCV effect was not due to the direct 
inhibition of HCV NS5B. 
HCV IRES Activity. We next investigated whether the anti-HCV effects of these compounds 
could be correlated to down regulation of HCV IRES activity. Huh 7.5 cells were transfected with the 
pClneo-Rluc-IRES-Fluc reporter plasmid,18 in which Rluc was translated in a cap-dependent manner
and Fluc was translated via HCV IRES-mediated initiation, and treated with increasing concentrations 
of compound 12, as a representative of this series. The results (data not shown) clearly indicated that 12 
had no effect on the HCV IRES mediated translation, thus ruling out interference with this mechanism 
of action. 
HCV modulates COX-2 expression.  HCV has been reported to stimulate COX-2 expres-
sion.19 We therefore investigated the levels of COX-2 in MH-14 cells, which autonomously replicate 
the HCV subgenomic replicon 1b.20 In agreement with previous findings, we noted >5-fold upregula-
tion of COX-2 promoter-linked luciferase reporter activity in MH-14 cells relative to their parental 
counterparts Huh-7 and Huh-7.5 cells (Figure 2A).  Concomitantly, the COX-2 mRNA and protein lev-
els were quantitatively increased by ≥4-fold in MH-14 cells compared to Huh-7.5 cells (Figures 2B and 
2C). This data supports the up-regulation of COX-2 by HCV. 
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Figure 2. HCV induces COX-2 expression. (A) HCV activates COX-2 gene promoter activity. The pCOX-2-Luc reporter 
plasmid encoding firefly luciferase under the control of the COX-2 promoter was transfected in Huh-7, Huh7.5 and MH-14 
cells and 48 h post-transfection cell lysates were subjected to luciferase activity assay.  Fold increase of relative luciferase 
activity in Huh7.5 and MH-14 cells in comparison  to Huh-7 cells is shown. (B) COX-2 protein and mRNA levels in HCV 
replicon. Huh7.5 and MH-14 cells were cultured and processed for analysis of COX-2 protein and mRNA levels respective-
ly by western blotting (WB) and RT-PCR. β-Actin detection was used as to normalizer. NS5A and NS5B immunoblotting 
detection and HCV RNA PCR amplification were considered as markers for HCV replication in MH-14 cell line. and (C). 
Densitometric quantitation of Cox-2 immunoblotting and PCR amplified bands analysed by ImageJ software. Data are the 
average of three independent experiments performed in duplicate. ** P˂0.01. 
Compound 12 suppresses COX-2 expression. To investigate the effect of compound 12 on 
HCV-induced COX-2 expression, we analyzed the transcription and translation levels of COX-2 in 
compound 12-treated MH-14 cells. The COX-2 promoter-linked luciferase reporter assay revealed a
dramatic suppression of the COX-2 promoter reporter in a concentration-dependent manner (Figure
3A). This corresponded to 35% and 68% suppression at 2.8 μM and 4.4 μM, respectively of compound
12 concentration, and near complete abolition above 14 μM, thus yielding an inhibitory concentration 
(IC50) = 3.2 μM. These results indicate that 12 may mediate its antiviral effects through  inhibition of 
COX-2 mRNA transcripts. 
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Figure 3. Effect of 12 on HCV-induced COX-2 expression (A to C) Concentration-dependent inhibition of COX-2 promot-
er activity (A), protein synthesis (B) and RNA transcription (C) by 12. For the promoter activity assay (A), MH-14 cells 
were transiently transfected with the COX-2 promoter reporter plasmid pCOX-2-Luc and treated for 48 h with DMSO (ctr) 
or the indicated concentrations of 12. The percent decrease of relative luciferase activity (RLU) in 12-treated MH-14 cells 
relative to DMSO-treated cells, arbitrarily set at 100% for reference is shown. The RLU of pCOX-2-Luc-transfected-Huh-7 
cells is shown for comparison. For protein ) and RNA analysis (B, and C), MH-14 cells were incubated with increasing con-
centrations of 12 for 48 h. Total cell lysates were extracted and analyzed by Western blotting with anti-COX-2 and anti-β-
Actin (loading control) antibodies. Total RNA in 12-treated MH-14 cells was extracted and quantified by qRT-PCR for 
relative levels of COX-2 mRNA and HCV RNA, normalized against β-Actin mRNA. (C ) Densitometric analysis of HCV 
RNA and COX-2 protein  levels. Values reported are percent fold change with respect to control cells. Error bars represent 
SD from three independent experiments performed in duplicate. *P˂0.05; **P˂0.01. 
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Further, the specificity of  compound 12 on COX-2 promoter was evident from our findings that
at 50 µM concentration, 12 displayed no effect on the promoter-linked luciferase reporter assay for 
HO-1, Nrf2 or ISGs in MH-14 cells (data not shown), thus ruling out the transcriptional regulation of 
these host factors as the potential mechanism of this compound scaffold. 
We next investigated the effect of 12 on COX-2 mRNA and protein synthesis in relation to 
HCV replication inhibition. Towards this aim, MH-14 cells were incubated with 12 at increasing doses 
for 48 h and subjected to analysis of endogenous levels of COX-2 protein and mRNA expression and 
concomitant HCV RNA levels evaluation (Figures 3B and 3C). We observed that the synthesis of
COX-2 protein was supressed in a concentration dependent manner in 12-treated MH-14 cells (Figure 
3B). This was reflected by ~50% decrease of endogeneous COX-2 expression at 5 μM and near com-
plete abolition above 15 μM, consistent with the trend seen with the COX-2 promoter-linked luciferase 
reporter assay (Figure 3A). 
The 12-mediated suppression of COX-2 appeared to be specific as deduced from the expression 
levels of β-actin under similar treatment conditions. Notably, 12-mediated suppression of COX-2 pro-
tein expression (Figure 3B) exhibited a correlative trend with levels of COX-2 mRNA and a concomi-
tant decrease in HCV RNA (Figure 3C). This data indicates that compound 12 inhibits HCV RNA rep-
lication via attenuating COX-2 mRNA transcription and consequent suppression of COX-2 protein syn-
thesis. 
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Figure 4. Dose dependent restoration of 12-mediated suppression of HCV replication upon exogenous COX-2 expression. 
MH14 cells were transfected with the indicated amounts of pCMV-COX-2-Myc plasmid encoding cox-2 and 6 h post-
transfection, treated with either DMSO (control) or 25 µM compound 12 for 72 h. Cell lysates were analysed by Western 
blotting (WB) for expression of COX-2 and β-Actin as loading control (A, bottom two panels).  In another set, total RNAs 
were subjected to qRT-PCR to evaluate HCV RNA levels (A, top two panels). B depicts the quantification of HCV RNA
and COX-2 expression level with respect to control. The values represent the average ± SD from three independent experi-
ments.  
Exogenous expression of COX-2 abrogates 12-mediated inhibition of HCV RNA replica-
tion. To further investigate at the molecular level the role of COX-2 down-regulation in 12-mediated 
inhibition of HCV replication, we resorted to transient overexpression of COX-2 and analyzed the anti-
HCV effects of compound 12 under these conditions. MH-14 cells were transfected with either a con-
trol vector (pcDNA4/myc-His-A) or increasing concentrations of  pCMV-COX-2-Myc plasmid and 
subsequently treated with 12 at 25 µM, a concentration that inhibited HCV-induced COX-2 expression 
and HCV replication by >90% (Figure 3C). RT-PCR and Western blotting analysis revealed a complete 
knock-down of  HCV RNA (top) and COX-2 expression (bottom), in 12-treated cells relative to DMSO 
treated control cells (Figure 3A, compare lane 2 to 1). A dose-dependent increase of exogenous COX-
2-Myc resulted in a gradual restoration of HCV RNA levels in 12-treated cells (Figure 4A, lanes 3-6). 
This corresponded to quantitative recovery of HCV RNA levels by 50% and 100% in 12-treated cells at 
0.4 µg and above 0.8 µg of pCMV-COX-2-Myc plasmid, respectively (Figure 4B).   
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Table 2. Prediction of drug-like properties of 4, 5, 7, 11 and 12. 
Compd MWa SASAb Volc 
Donor 
HBd 
Accpt 
HBe 
QP 
polrzf 
Qplog 
C16g 
Qplo 
Pocth 
Qplo 
Pwi 
Qplo 
Po/wj QPlogSk PHOAl 
4 328.37 634.61 1084.9 1 3.5 41.45 12.96 17.79 10.03 4.85 -6.235 100 
5 362.37 660.62 1133.4 1 3.5 42.95 13.62 18.78 9.81 5.38 -7.018 100 
7 387.82 685.95 1187.6 1 5 44.27 14.38 21.36 11.30 4.74 -7.749 100 
11 422.27 692.02 1215.7 1 5 44.78 14.65 20.41 10.90 5.12 -8.173 100 
12 342.40 651.35 1133.8 1 3.5 43.06 13.18 18.07 9.82 5.13 -6.538 100 
aMW, molecular weight; bSASA, total solvent accessible surface area (range, 300–1000 Å2); cVolume, total solvent accessi-
ble area (range: 500–2000 Å3); dH-bond donors; eH-bond acceptors; fQPpolrz, Predicted polarizability (range, 13–70 Å3); 
gQPlogPC16, predicted log of hexadecane ⁄gas partition coefficient (range, 4–18); hQPlogPoct, predicted log of octanol ⁄gas 
partition coefficient (range, 8–43); iQPlogPw, predicted log of water ⁄ gas partition coefficient (range, 5–48); jQPlogPo ⁄w 
predicted log of octanol ⁄water partition coefficient (range -2 to 6); kQplogS, predicted log of aqueous solubility (range, -6 to 
0.5 M); lPHOS per cent human oral absorption. 
This data indicates that exogenous COX-2 expression abrogates 12-mediated anti-HCV activity. 
Taken together, our findings suggest that 12 mediates its anti-HCV effects via targeting COX-2. This 
supports targeting COX-2 as a viable strategy for anti-HCV inhibitor development and is in agreement 
with some previous  studies.21-23 
Prediction of drug-like properties. Drug likeness involves molecular features that mainly de-
scribe whether the molecule resembles the properties of known drugs. The drug-like properties of our 
compounds (Table 2) as predicted employing QikProp software,24 fall within the refernce ranges (Table
2 caption) of the 95% of used drugs, with the only violation of the QplogS values. These data highlight 
an interesting drug-like profile of these HCV agents representing a good basis for further development. 
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CONCLUSION 
The present study describes the synthesis and biological evaluation of a series of 1-phenyl-5-
(1H-pyrrol-1-yl)pyrazolecarboxamides as a new class of anti-HCV agents. Our results show that the
pyrazolecarboxamides inhibited HCV replication without causing host cellular toxicity. Significantly, 
four compounds bearing this scaffold exerted strong antiviral effects on both HCV genotype 1b and 2a. 
Of these, compound 12 proved to be the most promising, exhibiting an EC50 value of 6.7 μM and selec-
tivity index of 23 against HCV 1b, and reducing the RNA copies of the infectious Jc1 chimeric 2a 
clone by 82% at 7 μM. The  anti-HCV activity of compound 12 was identified to be mediated by COX-
2 inhibition, at both the transcriptional and translational levels. The broad range and strong antiviral ac-
tivities against HCV genotype 1b and 2a of the pyrazolcarboxamide compounds, the interesting molec-
ular mechanism  of anti-HCV activity,  that  targets  host factor dysregulated during viral infection, to-
gether with their drug likeness properties, serve as a strong basis for further optimization of this new 
chemical class of HCV inhibitors. 
EXPERIMENTAL SECTION 
Chemistry. Melting points (mp) were determined on a Stuart Scientific SMP1 apparatus and are uncor-
rected. Infrared spectra (IR) were run on a Perkin-Elmer SpectrumOne FT-ATR spectrophotometer. 
Band position and absorption ranges are given in cm−1. Proton nuclear magnetic resonance (1H NMR) 
spectra were recorded on a Bruker 400 MHz FT spectrometer in the indicated solvent and correspond-
ing fid files processed by MestreLab Research S.L. MestreReNova 6.2.1-769 software. Chemical shifts 
are expressed in δ units (ppm) from tetramethylsilane. Column chromatography was performed on col-
umns packed with alumina from Merck (70−230 mesh) or silica gel from Macherey-Nagel (70-230 
mesh). Aluminum oxide thin layer chromatography (TLC) cards from Fluka (aluminum oxide precoat-
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ed aluminum cards with fluorescent indicator detectable at 254 nm) and silica gel TLC cards from Ma-
cherey-Nagel (silica gel precoated aluminum cards with fluorescent indicator detectable at 254 nm) 
were used for TLC. Developed plates were visualized by a Spectroline ENF 260C/FE UV apparatus. 
Reagents and solvents from commercial sources were used without further purification. Organic solu-
tions were dried over anhydrous Na2SO4. Evaporation of the solvents was carried out on a Büchi rota-
vapor R-210 equipped with a Büchi V-855 vacuum controller and a Büchi V-700 or V-710 vacuum 
pump. Elemental analyses of the compounds were found within ± 0.4% of the theoretical values. The 
purity of tested compounds was >95%. For RdRp assays, compounds were dissolved in DMSO as 10 
mM stocks and serially diluted in DMSO immediately prior to the use. 
General Procedure for the Synthesis of Carboxamides 5-19. Example. N-(4-Chlorophenyl)-
1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (5). To a mixture of 1-phenyl-5-(1H-pyrrol-
1-yl)-1H-pyrazole-3-carboxylic acid (0.25 g, 1.0 mmol) (22).11c in anhydrous THF (14 mL) was added
1,1’-carbonyldiimidazole (0.18 g, 1.0 mmol) under Ar stream. The reaction mixture was stirred for 2 h 
at room temperature. 4-Chloroaniline (0.20 g, 1.5 mmol) was added and the reaction was stirred at 
room temperature for 24 h. The mixture was diluted with water and extracted with ethyl acetate. The 
organic layer was washed with brine, dried and filtered. Removal of the solvent gave a residue that was 
purified by column chromatography (silica gel, ethyl acetate/n-hexane 3:7 as eluent)  to provide 5 (0.27 
g, 75%), mp 140-145 oC (from ethanol). 1H NMR (DMSO-d6): δ 6.21-6.23 (m, 2H), 6.87-6.89 (m, 2H), 
7.10 (s, 1H), 7.29-7.31 (m, 2H), 7.39-7.46 (m, 5H), 7.85-7.88 (dd,  J = 9.2 and 1.8 Hz, 2H), 10.40 ppm 
(br s, disappeared on treatment with D2O, 1H). IR: ν 1678, 3382 cm-1. Anal. (C20H15ClN4O (362.81)) C, 
H, N, Cl 
4-Cyano-N,1-diphenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (6). Was synthesized as 
5 from 4-cyano-1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxylic acid (23) and aniline. Yield 
44%, mp 180-185 oC (from ethanol). 1H NMR (DMSO-d6): δ 6.29-6.31 (m, 2H), 6.99-7.01 (m, 2H), 
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7.14 (t, J = 6.9 Hz, 1H), 7.35-7.40 (m, 4H), 7.49-7.51 (m, 3H), 7.81-7.83 (d, J =7.8 Hz, 2H), 10.60 ppm 
(br s, disappeared on treatment with D2O, 1H). IR: ν 1684, 3299 cm-1. Anal. (C21H15N5O (353.38)) C, 
H, N. 
N-(4-Chlorophenyl)-4-cyano-1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (7). 
Was synthesized as 5 from 23 and 4-choroaniline. Yield 42%, mp 197-201 oC (from ethanol). 1H NMR 
(DMSO-d6): δ 6.29-6.31 (m, 2H), 6.98-7.01(m, 2H), 7.38-7.44 (m, 4H), 7.48-7.52 (m, 3H), 7.86-7.88 
(d, J = 8.6 Hz, 2H), 10.75 ppm (br s, disappeared on treatment with D2O, 1H)  IR: ν 1678, 3318 cm-1. 
Anal. (C21H14ClN5O (387.82)) C, H, N, Cl. 
1-(4-Chlorophenyl)-N-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (8). Was synthe-
sized as 5 from 1-(4-chlorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxylic acid (24) and aniline. 
Yield 44%, mp 190-195 oC (from ethanol). 1H NMR (DMSO-d6): δ 6.23-6.26 (m, 2H), 6.89-6.91 (m, 
2H), 7.08-7.12 (m, 2H), 7.28-7.37 (m, 4H), 7.52-7.54 (d, J = 8.2 Hz, 2H), 7.80-7.82 (d, J = 8.0 Hz, 
2H), 10.24 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1675, 3391 cm-1. Anal. 
(C20H15ClN4O (362.81)) C, H, N, Cl. 
N,1-bis(4-Chlorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (9). Was synthesized 
as 5 from 24 and 4-choroaniline. Yield 44%, mp 198-200 oC (from ethanol). 1H NMR (DMSO-d6): δ 
6.24-6.26 (m, 2H), 6.90-6.92 (m, 2H), 7.11 (s, 1H), 7.28-7.30 (d, J = 8.7 Hz, 2H), 7.39-7.42 (d, J = 8.5 
Hz, 2H), 7.52-7.54 (d, J = 8.0 Hz, 2H), 7.85-7.87 (d, J = 8.8 Hz, 2H), 10.42 ppm (br s, disappeared on 
treatment with D2O, 1H). IR: ν 1685, 3395 cm-1. Anal. (C20H14Cl2N4O (397.26)) C, H, N, Cl. 
1-(4-Chlorophenyl)-4-cyano-N-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (10). 
Was synthesized as 7 from 1-(4-chlorophenyl)-4-cyano-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxylic 
acid (25) and aniline. Yield 40% mp 234-238 oC  (from ethanol). 1H NMR (DMSO-d6): δ 6.31-6.34 (m, 
2H), 7.00-7.02 (m, 2H), 7.15 (t, J = 7.08 Hz, 1H), 7.35-7.40 (m, 4H), 7.59-7.61 (d, J = 8.08 Hz, 2H), 
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7.81-7.83 (d, J = 7.68 Hz, 2H), 10.61 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1685, 
3337 cm-1. Anal. (C21H14ClN5O (387.82)) C, H, N, Cl. 
N,1-bis(4-chlorophenyl)-4-cyano-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (11). Was 
synthesized as 5 from 25 and 4-choroaniline. Yield 47%, mp 255-258 oC (from ethanol). 1H NMR 
(DMSO-d6): δ 6.31-6.33 (m, 2H), 6.99-7.01 (m, 2H), 7.38-7.44 (m, 4H), 7.58-7.61 (d, J = 8.7 Hz, 2H), 
7.85-7.87 (d, J = 8.7 Hz, 2H), 10.78 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1685, 
3323 cm-1. Anal. (C21H13Cl2N5O (422.27)) C, H, N, Cl. 
N,1-diphenyl-5-(1H-pyrrol-1-yl)-4-methyl-1H-pyrazole-3-carboxamide (12). Was synthesized 
as 7 from 4-methyl-1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxylic acid (26) and aniline. Yield 
62% mp 147-150 oC (from ethanol). 1H NMR (DMSO-d6): δ 2.15 (s, 3H), 6.26-6.28 (m, 2H), 6.90-6.92 
(m, 2H), 7.10 (t, J = 7.2 Hz, 1H), 7.24-7.26 (d, J = 6.7, 2H), 7.32-7.43 (m, 5H), 7.81-7.83 (d, J = 8.4 
Hz, 2H), 10.16 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1666, 3362 cm-1. Anal. 
(C21H18N4O (342.39)) C, H, N . 
N-(4-chlorophenyl)-4-methyl-1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (13). 
Was synthesized as 5 from 26 and 4-choroaniline. Yield 12%, mp 147-150 oC (from ethanol). 1H NMR 
(DMSO-d6): δ 2.15 (s, 3H), 6.25-6.27 (m, 2H), 6.89-6.91 (m, 2H), 7.23-7.25 (m, 2H), 7.37-7.41 (m, 
5H), 7.86-7.88 (d, J = 8.8 Hz, 2H), 10.34 ppm (br s, disappeared on treatment with D2O, 1H). IR: 
ν 1667, 3357 cm-1. Anal. (C21H17ClN4O (376.84)) C, H, N, Cl. 
1-(4-Chlorophenyl)-4-methyl-N-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (14). 
Was synthesized as 5 from 1-(4-chlorophenyl)-4-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxylic 
acid (27) and aniline. Yield 83% mp 155-158 oC (from ethanol). 1H NMR (DMSO-d6): δ 2.14 (s, 3H), 
6.28-6.30 (m, 2H), 6.91-6.93 (m, 2H), 7.10 (t, J = 6.7 Hz, 1H), 7.22-7.25 (m, 2H), 7.32-7.36 (m, 2H), 
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7.47-7.50 (m, 2H), 7.80-7.82 (d, J = 7.9 Hz, 2H), 10.19 ppm (br s, disappeared on treatment with D2O, 
1H). IR: ν 1680, 3355 cm-1. Anal. (C21H17ClN4O (376.84)) C, H, N, Cl. 
N,1-bis (4-Chlorophenyl)-4-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (15). Was 
synthesized as 5 from 1-(4-chlorophenyl)-4-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxylic acid 
(29) and 4-chloroaniline. Yield 11%, mp 179-182 oC  (from ethanol). 1H NMR (DMSO-d6): δ  2.14 (s, 
3H), 6.28-6.30 (m, 2H), 6.91-6.93 (m, 2H), 7.22-7.24 (d, J = 8.8 Hz, 2H), 7.39-7.41 (d, J = 8.8 Hz, 
2H), 7.48-7.51 (d, J = 8.8 Hz, 2H), 7.85-7.87 (d, J = 8.8 Hz, 2H), 10.36 ppm (br s, disappeared on 
treatment with D2O, 1H). IR: ν 1669, 3367 cm-1. Anal. (C21H16Cl2N4O (411.28)) C, H, N, Cl. 
N-(3,4-Dichlorophenyl)-1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (16). Was 
synthesized as 5 from 22  and 3,4-dichloroaniline. Yield 51%, mp 142-146 oC (from ethanol). 1H NMR 
(DMSO-d6): δ  6.20-6.22 (m, 2H), 6.87-6.89 (m, 2H), 7.11(s, 1H), 7.30-7.32 (m, 2H), 7.44-7.46 (m, 
3H), 7.60-7.62 (d, J = 8.8 Hz, 1H), 7.84-7.86 (dd, J = 2.2 and 8.6 Hz, 1H), 8.20 (s, 1H), 10.57 ppm (br 
s, disappeared on treatment with D2O, 1H). IR: ν 1693, 3367 cm-1. Anal. (C20H14Cl2N4O (397.26)) C, H, 
N, Cl. 
1-(4-Chlorophenyl)-N-(3,4-dichlorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide 
(17). Was synthesized as 5 from 24 and 3,4-dichloroaniline. Yield 53%, mp 165-171oC (from ethanol). 
1H NMR (DMSO-d6): δ  6.23-6.25 (m, 2H), 6.89-6.91 (m, 2H), 7.12 (s, 1H), 7.29-7.31 (d, J = 8.8 Hz, 
2H), 7.53-7.55 (d, J = 8.8 Hz, 2H), 7.60-7.63 (d, J = 8.8 Hz, 1H), 7.83-7.86 (dd, J = 2.4 and 8.8 Hz, 
1H,), 8.20 (s, 1H), 10.59 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1687, 3380 cm-1. 
Anal. (C20H13Cl3N4O (431.70)) C, H, N, Cl. 
4-Cyano-N-(3,4-dichlorophenyl)-1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide 
(18). Was synthesized as 5 from 23 and 3,4-dichloroaniline. Yield 10%, mp 213-219 oC (from ethanol). 
1H NMR (DMSO-d6): δ 6.29-6.31 (m, 2H), 6.99-7.01 (m, 2H), 7.38-7.40 (m, 2H), 7.49-7.51 (m, 3H), 
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7.63-7.65 (d, J = 8.4 Hz, 1H), 7.84-7.86 (d, J = 8.8 Hz, 1H), 8.21 (s, 1H), 10.92 ppm (br s, disappeared 
on treatment with D2O, 1H). IR: ν 1692, 3351 cm-1. Anal. (C21H13Cl2N5O (422.27)) C, H, N, Cl. 
1-(4-Chlorophenyl)-4-cyano-N-(3,4-dichlorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-
carboxamide (19). Was synthesized as 5 from 25 and 3,4-dichloroaniline. Yield 11%, mp 237-244 oC 
(from ethanol). 1H NMR (DMSO-d6): δ 6.31-6.33 (m, 2H), 6.99-7.01 (m, 2H), 7.38-7.40 (d, J = 8.4 Hz, 
2H), 7.59-7.65 (m, 3H), 7.82-7.85 (dd, J = 2.4 and 8.8 Hz, 1H), 8.19 (s, 1H), 10.93 ppm (br s, disap-
peared on treatment with D2O, 1H). IR: ν 1693, 3346 cm-1. Anal. (C21H12Cl3N5O (456.71)) C, H, N, Cl. 
General Procedure for the Synthesis of Carboxamides 4, 20 and 21. Example. 1-(4-
Chlorophenyl)-N-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxamide (20). A mixture of 1-(4-
chlorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylic acid (28)15 (0.25 g, 0.87 mmol), aniline
(0.23 g, 0.24 mL, 2.61 mmol), BOP reagent  (0.35 g, 0.87 mmol) and triethylamine (0.26 g, 0.36 mL, 
2.61 mol) in anhydrous DMF (8 mL) was stirred at room temperature overnight. The reaction mixture 
was diluted with brine and extracted with ethyl acetate. The organic layer was washed with brine, dried 
and filtered. Removal of the solvent gave a residue that  was purified by column chromatography (sili-
ca gel, n-hexane/ethyl acetate 2:1 as eluent) to provide  20 (40 mg, 13%), mp 181-185 °C (from etha-
nol). 1H NMR (DMSO-d6): δ 6.21-6.23 (m, 2H), 6.90-6.92 (m, 2H), 7.06 (t, J = 7.4 Hz, 1H), 7.10-7.13 
(dd, J = 1.8 and 8.7 Hz, 2H), 7.29-7.32 (m, 2H), 7.46-7.48 (dd, J = 2.1 and 8.9 Hz, 2H), 7.60-7.61 (d, J 
= 7.08, 2H), 8.43 (s, 1H), 9.77 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1665, 3386 
cm-1. Anal. (C20H15ClN4O (362.81)) C, H, N, Cl. 
N,1-bis(4-Chlorophenyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxamide (21). Was synthesized 
as 20 from 28 and 4-chloroaniline. Yield 59%, mp 177-181 oC (from ethanol). 1H NMR (DMSO-d6): δ 
6.20-6.22 (m, 2H), 6.88-6.90 (m, 2H), 7.11-7.13 (d, J = 8.6 Hz, 2H), 7.36-7.38 (d, J = 8.9 Hz, 2H), 
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7.46-7.48 (d, J = 8.6 Hz, 2H), 7.65-7.67(d, J = 8.9 Hz, 2H), 8.42 (s, 1H), 10.00 ppm (br s, disappeared 
on treatment with D2O, 1H). IR: ν 1670, 3388 cm-1. Anal. (C20H14Cl2N4O (397.26)) C, H, N, Cl. 
N,1-Diphenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide (4). Was synthesized as 20 from 
22 and aniline. Yield 70%, mp 114-115 oC (from ethanol). 1H NMR (CDCl3):  δ 6.29-6.31 (m, 2H), 
6.67-6.69 (m, 2H), 7.03-7.04 (m, 1H), 7.15-7.20 (m, 1H), 7.23-7.29 (m, 2H), 7.38-7.43 (m, 5H), 7.77-
7.75 (m, 2H), 8.80 ppm (br s, disappeared on treatment with D2O, 1H). IR: ν 1672, 3377 cm-1. Anal. 
(C20H16N4O (328.37)) C, H, N. 
Biology. Cell Culture. MH-14 cells expressing the HCV 1b subgenomic replicon, a kind gift
from Dr. Kunitada Shimotohno, were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invi-
trogen Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS),  100 U/ml penicil-
lin, 100 mg/mlstreptomycin,  2 mM L-glutamine and 0.5 mg/ mL G418. Huh 5.2 cells bearing the HCV 
1b I389luc-ubineo/NS3-3’/5.1 replicon were cultured in DMEM supplemented with 10% FCS, nones-
sential amino acids,. 100 U/ml penicillin, 100 mg/mlstreptomycin,  2 mM L-glutamine and 0.5 mg/ mL 
G418. Huh7.5, kindly provided by Apath were grown in DMEM supplemented with 10% FBS, 0.3 
mg/ml L-glutamine, 100U/ml penicillin, 100 mg/ml streptomycin and non essential amino acids. All 
cells were cultured at 37 oC in 5% CO2 atmosphere at 95-99% relative humidity. 
HCV Jc1 infection assay. The inhibitory effect of compounds 4, 6 and 12 on HCV infection 
was assayed employing the HCV genotype 2a infectious chimeric clone Jc1 (generous gift of C. Rice). 
Briefly, HCV-Jc1 virus stock of 105 TCID50/mL was used to infect Huh7.5 cell lines  at  1 m.o.i., in 12 
multi wells plates. Six hours post viral adsorption, cells were washed with PBS, supplemented with 
fresh media and incubated with the compounds at concentration specified in figure1 legend. Seventy-
two hours post-treatment, cells were harvested and processed for total RNA extraction employing 
RNeasy Mini Kit (Qiagen) in accordance with  the manufacturer's protocol. 
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HCV RNA quantitation by qRT-PCR. Quantitative One Step RT-PCR was carried out using 
an ABI 7000 real Time PCR System (Applied Biosystem). 5 µl of total RNA was mixed with 2x Taq-
Man One Step RT-PCR Master Mix (Applied Biosystem and 1 µM forward 
(TCCCGGGAGAGCCATAGT), 1µM reverse primers (CCCAGTCTTCCCGGCAATT) and 200 nM 
probe (FAM- CACCGGTTCCGCAGACC-TAMRA). In vitro transcribed genotype 2a RNA was used 
as a standard to quantify the copy numbers of viral RNA. 
Cell based inhibition and cytotoxicity assays. Inhibitory potency (EC50, EC90 values) and cy-
totoxicity (CC50 values) of the compounds were evaluated in Huh 5.2 cells as described previously.25
NS5B RdRp inhibition assay. The effect of the compounds on in vitro NS5B RdRp activity 
was investigated employing recombinant NS5B∆21 1b (HC-J4) and poly rA-U12 template-primer as de-
scribed previously.28 NS5B activity was determined relative to DMSO treated control that was set at
100% 
Transfection and luciferase reporter assay. MH-14 cells were seeded in 48 well plate (1x105 
cells/ well) and 12 h post seeding, transfected with 300 ng of gene specific reporter plasmid pCOX-2-
FLuc,21,25,26 pHO-1-Luc,27 pISRE-Luc28 or p3xARE-Luc29 using LipoD293 transfection reagent in ac-
cordance with the manufacturer’s protocol (SignaGen Lab, USA). Each transfection complex contained 
30 ng of Renilla luciferase reporter plasmid (pRL-SV40) as internal control for normalization of the 
transfection efficiency. Six hours post-transfection, cells were incubated with increasing concentrations 
of 12 (quarter log dilutions) or DMSO (control) for 48 hours. Luciferase activity assay was performed 
using the Dual-Glo Luciferase Assay Kit (Promega, USA) in accordance with the manufacturer’s in-
structions. 
To study the effect of 12 on HCV IRES mediated translation, Huh7.5 cells were seeded in 48 
well plate and transfected with pClneo-Rluc-IRES-Fluc (300 ng/well) reporter plasmid, in which Rluc 
was translated in a cap-dependent manner and Fluc was translated via HCV IRES-mediated initiation.18
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Six hours post-transfection, the cells were incubated with increasing concentrations of compound 12 or 
DMSO (control) for 48 hours. Luciferase activity assay was performed employing the Dual-Glo Lucif-
erase Assay Kit. 
Western blotting. Equal amounts of whole cell lysates (Dc protein assay, Bio-Rad) were re-
solved over 8% SDS-PAGE and gels were transferred to PVDF membrane by Trans Blot semi-dry 
transfer apparatus (Bio-Rad) and blots were blocked in 3% BSA for 1 h and probed with anti-NS5A, 
anti-NS5B, anti-Cox-2 and β-Actin antibodies. 
RT-PCR: Total RNA was isolated either using Triazol reagent (Life Technologies) or RNeasy 
mini kit (Promega Corp.). Isolated RNA’s were quantified using NanoDrop (ND1000, NanoDrop 
Technologies), and equal amount of RNA’s were reverse transcribed using Superscript II reverse tran-
scriptase (Life Technologies) using HCV specific or oligo dT18 as a primer by following manufactur-
er’s protocol in a final volume of 20 µl. Two micro liters of synthesized cDNA’s were used for down-
stream PCR applications using gene specific primers and Taq DNA polymerase (Sigma-Aldrich) in a 
final volume of 50 µl by following manufacturer’s protocol. For Cox-2 forward primer was 5’-
TGCAAGTTCTCCCGCTCC-3’ and reverse primer was 5’-CAGCATTTTGCCATCTTGTGAC-3’. The for-
ward and reverse primer sequences for β-Actin was 5’- AGCGAGCATCCCCCAAAGTT-3’ and 5’- 
GGGCACGAAGGCTCATCATT-3’, respectively. The HCV primers sequences were 5’-
CGGGAGAGCCATAGTGG-3’ for forward and 5’-AGTACCACAAGGCCTTTCG-3’ for reverse primer. 
ASSOCIATED CONTENT 
Supporting Information Available. Additional chemical information is available free of charge via 
the internet at http//pubs.acs.org. 
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ABBREVIATIONS USED 
HCV, hepatitis C virus; RdRp, RNA-dependent RNA polymerase; DAAs, direct-acting antiviral 
agents; COX-2, Cyclooxigenase-2; NS5B, Nonstructural protein 5B; m.o.i.: multiplicity of infection; 
DMEM, Dulbecco’s modified eagle medium; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium. 
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